Determining the level of miRNA 133a-5p and Mid Regional pro-Adrenomedullin in Patients with Stable Angina Pectoris
DOI:
https://doi.org/10.31351/vol34iss3pp54-64Abstract
Chronic stable angina pectoris (CSAP) is a prevalent heart disease which can be defined as a symptom or a clinical syndrome of stable coronary artery disease (CAD). CAD is usually caused by the presence of atherosclerotic plaques or blood clot within coronary arteries that may lead to ischemia. miRNA 133a is mainly expressed in the muscle and it has a role in apoptosis, angiogenesis, hypertrophy, atherosclerosis and ischemia. MR-proADM is of endothelial origin and produced by different sites in the body mainly by the heart, kidneys, lungs and adrenal medulla. MR-proADM plasma level is thought to be predictive of CAD. The aim of the current study was to detect the serum levels of microRNA 133a-5p and MR-proADM in a sample of Iraqi patients with chronic stable angina and obstructive CAD with normal LV ejection fraction so that to investigate whether these biomarkers can be used to diagnose those patients. In this case-control study, fasting venous blood samples were collected from 90 male and female subjects (40-76 years old) who were presented to the outpatient clinic as having chest pain. An electrocardiography, echocardiography and conventional coronary angiography were applied by the cardiologist for all the participants. Routine biochemical tests and patients questionnaire were also applied. Left ventricular ejection fraction was detected using the biplane M mode method. Accordingly, the patients who showed evidence of atherosclerotic plaque and CAD on the angiography were classified as angina patients (n=60) and those who showed no evidence of coronary obstruction and ischemia on the angiography (normal angiography) were classified as being a control group (n=30). The fold of gene expression of miRNA 133a-5p in serum and serum levels of MR-proADM, fasting blood glucose (FBG), urea, creatinine, TGs, total cholesterol, LDL-C, HDL-C and VLDL-C were measured. Results: the fold of miRNA 133a-5p gene expression in serum and the serum levels of MR-proADM were significantly higher in patients (P≤ 0.01) and ROC curve showed that miRNA 133a-5p had 98% sensitivity and 47% specificity with AUC=0.8, whereas, MR-proADM had 100% sensitivity and 100% specificity with AUC=1.0. So, it can be concluded that MR-proADM could be used as an independent biomarker for the diagnosis of stable angina patients with normal LV ejection fraction, whereas microRNA 133a-5p is better to be used in combination with other biomarkers to give more accurate diagnosis.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Farmakis D, Xanthopoulos A, Triposkiadis F. A critical appraisal of the pharmacological management of stable angina. Hellenic Journal of Cardiology. 2021 Mar 1;62(2):135–8.
Lucio SLD, Hernández MAL, Lucio SLD, Hernández MAL. Ischemic Heart Disease. In: Cardiomyopathy - Disease of the Heart Muscle [Internet]. IntechOpen; 2021 [cited 2023 May 11]. Available from: https://www.intechopen.com/chapters/77100.
Berry C. Stable Coronary Syndromes: The Case for Consolidating the Nomenclature of Stable Ischemic Heart Disease. Circulation. 2017 Aug;136(5):437–9.
Tamargo J, Lopez-Sendon J. Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable angina. Future Cardiology. 2022 Mar;18(3):235–51.
Criteria I of M (US) C on SSCD. Ischemic Heart Disease. In: Cardiovascular Disability: Updating the Social Security Listings [Internet]. National Academies Press (US); 2010 [cited 2023 May 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209964/
Hussain HAK, Muftin NQ, Al-jibouri MN, Ben Salah G. Study of the Arginase Activity and Other Biochemical Parameters in Patients with Coronary Artery Disease in Baghdad Governorate-Iraq. Al-Mustansiriyah Journal of Science. 2023 Mar 30;34(1):37–44.
Duggan JP, Peters AS, Trachiotis GD, Antevil JL. Epidemiology of Coronary Artery Disease. Surgical Clinics of North America. 2022 Jun 1;102(3):499–516.
Levin MG, Klarin D, Assimes TL, Freiberg MS, Ingelsson E, Lynch J, et al. Genetics of Smoking and Risk of Atherosclerotic Cardiovascular Diseases. JAMA Netw Open. 2021 Jan 19;4(1):e2034461.
GHARIB AF, SABER T, EL ASKARY A, ALHARTHI A, ALI ALSALMI N, TALAL ALHASHMI S, et al. Relation of Hypoxia Inducible Factor, Dyslipidemia and CAD Saudi Patients With Type 2 Diabetes. In Vivo. 2022 Sep 3;36(5):2481–9.
Brown JC, Gerhardt TE, Kwon E. Risk Factors For Coronary Artery Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 8]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554410/
Gillen C, Goyal A. Stable Angina. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 May 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559016/
Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European heart journal. 2020 Jan 14;41(3):407–77.
Di Carli MF, Gupta A. Estimating Pre-Test Probability of Coronary Artery Disease. JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1401–4.
Winther S, Schmidt SE, Rasmussen LD, Juárez Orozco LE, Steffensen FH, Bøtker HE, et al. Validation of the European Society of Cardiology pre-test probability model for obstructive coronary artery disease. European Heart Journal. 2021 Apr 7;42(14):1401–11.
Bertolone DT, Gallinoro E, Esposito G, Paolisso P, Bermpeis K, De Colle C, et al. Contemporary Management of Stable Coronary Artery Disease. High Blood Press Cardiovasc Prev. 2022;29(3):207–19.
Gibbons RJ, Miller TD. Declining Accuracy of the Traditional Diamond-Forrester Estimates of Pretest Probability of Coronary Artery Disease: Time for New Methods. JAMA Intern Med. 2021 May 1;181(5):579–80.
Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021 Apr 15;14(4):dmm047662.
Arif IS, Raoof IB, Luaibi HH, Ibraheem SK. Role of miRNA in drug-induced hepatic injury. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2022 Jul 5;22(2):1–6.
Radhi KA, Matti BF, Hamzah IH, Alkasir R. The role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients. Al-Mustansiriyah Journal of Science. 2023 Mar 30;34(1):16–22.
Zhou Y, Chen Z, Chen A, Ma J, Qian J, Ge J. Elevated serum miR-133a predicts patients at risk of periprocedural myocardial injury after elective percutaneous coronary intervention. Cardiol J. 2022 Apr 7;29(2):284–92.
Piubelli C, Meraviglia V, Pompilio G, D’Alessandra Y, Colombo GI, Rossini A. microRNAs and Cardiac Cell Fate. Cells. 2014 Sep;3(3):802–23.
Chistiakov DA, Orekhov AN, Bobryshev YV. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). Journal of Molecular and Cellular Cardiology. 2016 May 1;94:107–21.
Lu Y, Thavarajah T, Gu W, Cai J, Xu Q. The Impact of microRNA in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 Sep;38(9):e159–70.
Koyama T, Kuriyama N, Suzuki Y, Saito S, Tanaka R, Iwao M, et al. Mid-regional pro-adrenomedullin is a novel biomarker for arterial stiffness as the criterion for vascular failure in a cross-sectional study. Sci Rep. 2021 Jan 11;11(1):305.
Funke-Kaiser A, Mann K, Colquhoun D, Zeller T, Hunt D, Simes J, et al. Midregional proadrenomedullin and its change predicts recurrent major coronary events and heart failure in stable coronary heart disease patients: The LIPID study. International Journal of Cardiology. 2014 Mar;172(2):411–8.
Czajkowska K, Zbroch E, Bielach-Bazyluk A, Mitrosz K, Bujno E, Kakareko K, et al. Mid-Regional Proadrenomedullin as a New Biomarker of Kidney and Cardiovascular Diseases—Is It the Future? Journal of Clinical Medicine. 2021 Jan;10(3):524.
Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2021 Nov 30;78(22):e187–285.
Zheng L, Kang Y, Zhang L, Zou W. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR. Cancer Biol Ther. 2019 Nov 17;21(1):34–42.
N SY, Z A munim S, M FA. Gene Expression of miRNAs Let-7aAssociated with Diabetes in Iraqi Population. Archives of Razi Institute. 2021 Oct;76(4):1077.
Porzycki P, Ciszkowicz E, Semik M, Tyrka M. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int Urol Nephrol. 2018;50(9):1619–26.
Glover T. An Introduction to Biostatistics, Second Edition 2nd edition by Thomas Glover, Kevin Mitchell (2008) Paperback.
Forthofer RN, Lee ES, Hernandez M. Biostatistics: a guide to design, analysis, and discovery. 2nd ed. Burlington, MA: Elsevier Academic Press; 2007. 502 p.
www.heart.org [Internet]. [cited 2023 Nov 5]. Angina Pectoris (Stable Angina). Available from: https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain/angina-pectoris-stable-angina
Rieckmann N, Neumann K, Feger S, Ibes P, Napp A, Preuß D, et al. Health-related qualify of life, angina type and coronary artery disease in patients with stable chest pain. Health Qual Life Outcomes. 2020 May 14;18:140.
Kabłak-Ziembicka A, Badacz R, Przewłocki T. Clinical Application of Serum microRNAs in Atherosclerotic Coronary Artery Disease. Journal of Clinical Medicine. 2022 Jan;11(22):6849.
Koval SM, Snihurska IO, Yushko KO, Mysnychenko OV, Penkova MYu, Lytvynova OM, et al. Circulating microRNA-133a in Patients With Arterial Hypertension, Hypertensive Heart Disease, and Left Ventricular Diastolic Dysfunction. Front Cardiovasc Med. 2020 Jul 7;7:104.
Abdallah HY, Hassan R, Fareed A, Abdelgawad M, Mostafa SA, Mohammed EAM. Identification of a circulating microRNAs biomarker panel for non-invasive diagnosis of coronary artery disease: case–control study. BMC Cardiovasc Disord. 2022 Jun 24;22:286.
Hartopo AB, Puspitawati I, Anggraeni VY. High Level of Mid-Regional Proadrenomedullin during ST-Segment Elevation Myocardial Infarction Is an Independent Predictor of Adverse Cardiac Events within 90-Day Follow-Up. Medicina (Kaunas). 2022 Jun 28;58(7):861.
Mid-regional pro-adrenomedullin and lactate dehydrogenase as predictors of left ventricular remodeling in patients with myocardial infarction treated with percutaneous coronary intervention [Internet]. [cited 2023 Nov 5]. Available from: https://www.mp.pl/paim/issue/article/16150
Ali Sheikh MS. Diagnostic Role of Plasma MicroRNA-21 in Stable and Unstable Angina Patients and Association with Aging. Cardiol Res Pract. 2020 Apr 13;2020:9093151.
Shi S, Wang Z, Li S, Wu X, Wang P, Wang F. Yanyu Decoction for Aged Patients with Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis. Evid Based Complement Alternat Med. 2021 Apr 17;2021:6615035.
Severino P, D’Amato A, Pucci M, Infusino F, Adamo F, Birtolo LI, et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int J Mol Sci. 2020 Oct 30;21(21):8118.
Soliman SE, Abouelenin MAH, Samy NI, Omar MM, Alrefai AA. Various Expressions of PIK3C2A and TXNIP Genes and Their Potential Role as Independent Risk Factors for Chronic Stable Angina and Acute Coronary Syndrome. Biomolecules. 2023 Feb 6;13(2):302.
Shatari SAEA, Juboori YBHA, Salih K, Abed AS, Gabur AS, Witwit SA, et al. Effect of Health education on Blood Pressure Control & Life Modification in Hypertensive Patients: Sample from Primary Health Care centers, Al -Rusafa Sector/Baghdad. IRAQI JOURNAL OF COMMUNITY MEDICINE [Internet]. 2021 [cited 2023 Oct 26];34(2). Available from: https://www.iasj.net/iasj/article/234318
Dababneh E, Goldstein S. Chronic Ischemic Heart Disease Selection of Treatment Modality. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 14]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK507703/
Fadhil S, Elaebi H, Abbas S. Assessment of the left ventricular performance in hypertensive patients with normal coronary angiography and ejection fraction: Insight by two-dimensional speckle tracking echocardiography. Mustansiriya Med J. 2022;21(1):68.
Wang X, Xu W, Song Q, Zhao Z, Meng X, Xia C, et al. Association between the triglyceride–glucose index and severity of coronary artery disease. Cardiovasc Diabetol. 2022 Sep 1;21:168.
Karagiannidis E, Moysidis DV, Papazoglou AS, Panteris E, Deda O, Stalikas N, et al. Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease. Cardiovasc Diabetol. 2022 May 7;21:70.
Costa J, Alarcão J, Araujo F, Ascenção R, Caldeira D, Fiorentino F, et al. The burden of atherosclerosis in Portugal. Eur Heart J Qual Care Clin Outcomes. 2020 Sep 18;7(2):154–62.
Wang X, Chen LL, Zhang Q. Increased Serum Level of Growth Differentiation Factor 15 (GDF-15) is Associated with Coronary Artery Disease. Cardiovascular Therapeutics. 2016;34(3):138–43.
Farhood HH, Abdulridha MK, Hadi H. The Association between Adverse Pregnancy Outcomes and Laboratory Measures as Risk for Cardiovascular Disorders. Al Mustansiriyah Journal of Pharmaceutical Sciences. 2023 May 22;23(2):127–39.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
